<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://www.dailypolitical.com//rss/</forum>
<forum_title>Daily Political</forum_title>
<discussion_title>Evgen Pharma PLC (EVG) Stock Rating Lowered by Beaufort Securities</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.dailypolitical.com/2016/08/22/evgen-pharma-plc-evg-stock-rating-lowered-by-beaufort-securities/</topic_url>
<topic_text>
Tweet 
Evgen Pharma PLC (LON:EVG) was downgraded by equities researchers at Beaufort Securities to a “hold” rating in a research note issued on Thursday. 
Separately, Northland Securities reissued a “buy” rating and set a GBX 79 ($1.02) target price on shares of Evgen Pharma PLC in a research report on Wednesday, August 17th. 
Shares of Evgen Pharma PLC ( LON:EVG ) opened at 26.07 on Thursday. The firm’s 50-day moving average price is GBX 18.42 and its 200 day moving average price is GBX 19.36. The company’s market capitalization is GBX 19.07 million. Evgen Pharma PLC has a 1-year low of GBX 14.50 and a 1-year high of GBX 45.00. 
Evgen Pharma PLC is a United Kingdom-based clinical-stage drug development company. The Company’s lead programs are focused on the treatment of cancers, such as breast and prostate cancer, and neurological conditions, such as subarachnoid hemorrhage. The Company has completed Phase I trials for its development product, SFX-01.   Evgen Pharma PLC   Evgen Pharma PLC  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.dailypolitical.com/2016/08/22/evgen-pharma-plc-evg-stock-rating-lowered-by-beaufort-securities/</post_url>
<post_date>20160822</post_date>
<post_time>0802</post_time>
<username>Latisha Jones</username>
<post>
Tweet 
Evgen Pharma PLC (LON:EVG) was downgraded by equities researchers at Beaufort Securities to a “hold” rating in a research note issued on Thursday. 
Separately, Northland Securities reissued a “buy” rating and set a GBX 79 ($1.02) target price on shares of Evgen Pharma PLC in a research report on Wednesday, August 17th. 
Shares of Evgen Pharma PLC ( LON:EVG ) opened at 26.07 on Thursday. The firm’s 50-day moving average price is GBX 18.42 and its 200 day moving average price is GBX 19.36. The company’s market capitalization is GBX 19.07 million. Evgen Pharma PLC has a 1-year low of GBX 14.50 and a 1-year high of GBX 45.00. 
Evgen Pharma PLC is a United Kingdom-based clinical-stage drug development company. The Company’s lead programs are focused on the treatment of cancers, such as breast and prostate cancer, and neurological conditions, such as subarachnoid hemorrhage. The Company has completed Phase I trials for its development product, SFX-01.   Evgen Pharma PLC   Evgen Pharma PLC  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.dailypolitical.com/logos/evgen-pharma-plc-logo.png</main_image>
</document>
